Holen Sie sich die Stockscreener-App
6.285
0.16%
0.095
Schlusskurs vom Vortag:
$6.19
Offen:
$6.4147
24-Stunden-Volumen:
5,104
Relative Volume:
0.01
Marktkapitalisierung:
$3.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.47M
KGV:
-0.1615
EPS:
-38.9215
Netto-Cashflow:
$-8.38M
1W Leistung:
-4.91%
1M Leistung:
+759.92%
6M Leistung:
+76.64%
1J Leistung:
-55.84%
1-Tages-Spanne:
$6.21
$6.4147
1-Wochen-Bereich:
$5.918
$6.805
52-Wochen-Spanne:
$0.52
$19.91
Artelo Biosciences Inc Stock (ARTL) Company Profile
Firmenname
Artelo Biosciences Inc
Sektor
Branche
Telefon
858-925-7049
Adresse
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
6.2216 | 3.39M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Eingeleitet | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo! Finance Canada
Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade
Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us
Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Artelo Biosciences Inc (NASDAQ: ARTL) Share Price, ARTL Stock News, ARTL Share Price & Updates - kalkine.ca
Artelo Biosciences Inc. (ARTL) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Artelo Biosciences To Carry Out 1-for-9 Reverse Stock Split On August 31st, 2026 - Moomoo
Artelo Biosciences Inc. (ARTL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com India
Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31 - Stock Titan
Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com Canada
Artelo Biosciences Announces Reverse Stock Split - Barchart.com
Artelo Biosciences will combine every 9 shares into 1 starting Aug. 31 - Stock Titan
Artelo (ARTL) Technicals: Declines 2.86% to $0.69 at the Close; Range View - vinanet.vn
Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus
Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget
Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies - Yahoo Finance
ARTL Q2 2026 Earnings: Reported EPS of -$0.89 Reflects Continued Development FocusROIC Trend Report - vinanet.vn
ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com
Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade
Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan
Artelo Biosciences Q2 Net Income USD -2.4 Mil - Moomoo
Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain - Stock Titan
Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan
Artelo Biosciences Q2 FY26 net loss narrows 24.65% to USD 2.43 million - Bitget
Artelo Biosciences (ARTL) Advances 6.34% to $0.75 as Micro-Cap Biotech Tests Key ResistanceDebt Free Companies - vinanet.vn
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo doses first patient in glaucoma study for ART27.13 - Investing.com
Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure - Stock Titan
Price to book forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Enterprise value to EBIT forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Artelo Biosciences (ARTL) Slips to $0.73 as Biotech Names Face Renewed Selling PressureLow Risk Entry Stocks - dars.gov.et
ARTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ARTL Q4 2025 Earnings: 97.5% EPS Surprise as Net Loss Narrowly Beats EstimatesEPS Surprise History - vinanet.vn
Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - TradingView
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences (ARTL) Edges Higher Near Resistance: Key Levels to WatchGrowth Factor - vinanet.vn
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - marketscreener.com
Finanzdaten der Artelo Biosciences Inc-Aktie (ARTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):